Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

Key Takeaways Sanofi's Dupixent is now approved by the FDA for treating bullous pemphigoid in U.S. adults. The approval is backed by phase II/III data showing better remission and reduced steroid use. Dupixent's expanding label reinforces its role in treating type II inflammation-driven diseases.Sanofi (SNY) and its partner, Regeneron (REGN) , announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP), a rare skin ...